Want to see CING full AI Analyst Report?
CING Stock Chart & Stats
$5.32
-$0.13(-2.91%)
At close: 4:00 PM EDT
$5.32
-$0.13(-2.91%)
Day’s Range― - ―
52-Week Range$3.16 - $11.89
Previous CloseN/A
Volume78.30K
Average Volume (3M)128.69K
Market Cap
$74.02M
Enterprise Value$50.02
Total Cash (Recent Filing)$28.40M
Total Debt (Recent Filing)$6.29M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 18, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.01
Shares Outstanding14,541,826
10 Day Avg. Volume79,962
30 Day Avg. Volume128,694
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.40
Price to Sales (P/S)0.00
P/FCF Ratio-1.35
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$20.33Price Target Upside282.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual Property ProtectionThe patent provides long-duration protection for CTx-1301’s formulation and release mechanism, potentially supporting future commercial exclusivity and strengthening the Precision Timed Release platform’s competitive position.
Lead Asset DevelopmentThe absence of identified clinical safety or efficacy concerns preserves the therapeutic rationale for CTx-1301. Completing manufacturing work and resubmitting could keep the lead program viable despite the regulatory setback.
Proprietary Drug Delivery PlatformA proprietary, precision-timed delivery approach could differentiate Cingulate’s candidates by targeting sustained, once-daily symptom coverage. The platform may also support expansion into related ADHD and anxiety indications.
Bears Say
No Revenue And Persistent LossesCingulate remains pre-commercial, with no reported revenue and recurring operating and net losses. Widening losses increase dependence on external financing and leave future value heavily dependent on successful product approval and launch.
Sustained Cash BurnPersistent operating and free-cash-flow deficits show that the business cannot yet fund development internally. Continued clinical, manufacturing and regulatory spending may require additional capital before any product revenue is generated.
Regulatory Delay And Financing RiskThe FDA response delays potential commercialization and extends the time before CTx-1301 can generate revenue. The added development period may increase cash needs and financing risk while the company completes CMC work.
Cingulate Inc News
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $3.16 and its highest was $11.89 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $74.02M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is Nov 18, 2026 which is in 61 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Aug 13, 2026. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.625 by $0.175.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -0.43.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 14,541,826 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.625. Following the earnings report the stock price went down -4.223%.
Which hedge fund is a major shareholder of Cingulate Inc?
Currently, no hedge funds are holding shares in CING
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cingulate Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (282.21% Upside)
$20.33 (282.21% Upside)
Hedge Fund Trend
Decreased
By 97.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
145.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cingulate Inc
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
CING Stock 12 Month Forecast
Average Price Target
$20.33
▲(282.21% Upside)
Technical Analysis
Medicinova
―
Clene
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
1.78% Insiders
2.59% Mutual Funds
0.64% Other Institutional Investors
90.98% Public Companies and
Individual Investors